OncoMatch/Prostate Cancer/CDK12
Prostate CancerCDK12 Clinical Trials
CDK12 biallelic inactivation occurs in approximately 5% of mCRPC and defines a genomic subtype characterized by focal tandem duplications, neoantigen burden, and potential immunotherapy sensitivity — distinct from MSI-H. CDK12-mutant prostate cancer has shown signals of response to PD-1 blockade in basket trials. Trials investigate checkpoint immunotherapy alone or in combination with PARP inhibitors, AR-targeted agents, and novel CDK inhibitors in CDK12-deficient mCRPC.
Top recruiting CDK12 Prostate Cancer trials
Ranked by phase and US site count. See all 6 trials matched to your profile →
Platinum and Taxane Chemo in Met Castration Resistant Prostate Cancer Patients With Alterations in DNA Damage Response Genes
Canadian Cancer Trials Group
High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers
VA Office of Research and Development
Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations
Rana McKay, MD
A Study of Talazoparib With or Without Enzalutamide in People With Prostate Cancer Who Have Previously Received Abiraterone Acetate
Prostate Cancer Clinical Trials Consortium
RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure
Tianjin Medical University Second Hospital
A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
IDEAYA Biosciences
Browse other molecular targets with active Prostate Cancer trials.